2025年Nerocrine Biosciences的2025年收入略微失利,但销售量激增,毒品表现强劲,预计2026年Ingrezza的销售额为27—28亿美元。 Neurocrine Biosciences' 2025 earnings missed slightly, but sales surged, with strong drug performance and a $2.7–$2.8 billion Ingrezza sales projection for 2026.

Neurocrine Biosciences公布2025年第四季度每股收益为1.88美元，略低于预期，但收入达到8.055亿美元，同比增长28.3%。 Neurocrine Biosciences reported fourth-quarter 2025 earnings of $1.88 per share, slightly below expectations, though revenue hit $805.5 million, up 28.3% year-over-year. 产品销售总额超过28亿美元,这是英格雷斯扎公司和Crenessity公司业绩强劲推动的,该公司在第一年全年超过3亿美元。 Total product sales exceeded $2.8 billion, driven by strong performance from Ingrezza and Crenessity, which surpassed $300 million in its first full year. 该公司预测Ingrezza的销售额在2026年为27—28亿美元,得到扩大准入和不断增长的销售力量的支持。 The company projected Ingrezza sales of $2.7–$2.8 billion in 2026, supported by expanded access and a growing salesforce. 预期在2027年,两个阶段3神经精神病试验将在2027年提供一线数据,而第二阶段的迟滞症试验正在进行中。 Two Phase 3 neuropsychiatry trials are expected to deliver top-line data in 2027, while a Phase 2 trial for tardive dyskinesia is underway. 该公司年终现金为25亿美元,净利润为15.95%,协商一致的“货币购买”评级为176美元价格目标。 The company ended the year with $2.5 billion in cash, a 15.95% net margin, and a consensus "Moderate Buy" rating with a $176 price target.